Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products
CC-1065, the duocarmycins and yatakemycin are members of a family of ultrapotent antitumour antibiotics that have been the subject of extensive investigations due to their mode of action and potential in the design of new anticancer therapeutics. The natural products and their analogues exert their...
Saved in:
Published in | Current topics in medicinal chemistry Vol. 9; no. 16; p. 1494 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United Arab Emirates
01.11.2009
|
Subjects | |
Online Access | Get more information |
ISSN | 1873-4294 |
DOI | 10.2174/156802609789909812 |
Cover
Loading…
Abstract | CC-1065, the duocarmycins and yatakemycin are members of a family of ultrapotent antitumour antibiotics that have been the subject of extensive investigations due to their mode of action and potential in the design of new anticancer therapeutics. The natural products and their analogues exert their effects through a sequence selective alkylation of duplex DNA in the minor groove at the N3 of adenine. An understanding of their structure and its effect on biological activity has been derived through chemical synthesis and has also generated new potential lead compounds. These studies form the first section of the review. The desire to progress these compounds to clinic has also led to studies of bioconjugation and prodrug formation and this is discussed in the second section of the review. The combination of synthesis with key biological experiments is a powerful tool to define the requirements for the development of natural products as potential therapeutic agents. The studies described herein form an excellent paradigm for the study and development of other natural products. |
---|---|
AbstractList | CC-1065, the duocarmycins and yatakemycin are members of a family of ultrapotent antitumour antibiotics that have been the subject of extensive investigations due to their mode of action and potential in the design of new anticancer therapeutics. The natural products and their analogues exert their effects through a sequence selective alkylation of duplex DNA in the minor groove at the N3 of adenine. An understanding of their structure and its effect on biological activity has been derived through chemical synthesis and has also generated new potential lead compounds. These studies form the first section of the review. The desire to progress these compounds to clinic has also led to studies of bioconjugation and prodrug formation and this is discussed in the second section of the review. The combination of synthesis with key biological experiments is a powerful tool to define the requirements for the development of natural products as potential therapeutic agents. The studies described herein form an excellent paradigm for the study and development of other natural products. |
Author | Sheldrake, Helen M Pors, Klaus Searcey, Mark Ghosh, Nandita |
Author_xml | – sequence: 1 givenname: Nandita surname: Ghosh fullname: Ghosh, Nandita organization: Institute of Cancer Therapeutics, School of Life Sciences, University of Bradford, West Yorkshire BD7 1DP, UK – sequence: 2 givenname: Helen M surname: Sheldrake fullname: Sheldrake, Helen M – sequence: 3 givenname: Mark surname: Searcey fullname: Searcey, Mark – sequence: 4 givenname: Klaus surname: Pors fullname: Pors, Klaus |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19903166$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j0tLw0AAhBdRtFb_gAfZPxDd9-MoQatQ8NJ72addSHbDJgHz722rnoZvhhmYW3CZSw4APGD0RLBkz5gLhYhAWiqtkVaYXIAVVpI2jGh2DW7w0aZYiBWw7SH0yZkOmuyhTaUrX2cM30NXqplSySMsEU6HAKPpU7ecqG0bjAQ_l06Jn4sztV9cyjCbaa7HhaEWP7tpvANX0XRjuP_TNdi9ve7a92b7ufloX7aNZYJPDRGYOqQEYZ4xFqKMgQjtvENIOk4pMox4TiL2lmKJlNLCIk0FJ9RRb8kaPP7ODrPtg98PNfWmLvv_r-QHtDxS-w |
CitedBy_id | crossref_primary_10_1021_acs_orglett_6b03209 crossref_primary_10_1016_j_tet_2013_10_012 crossref_primary_10_1016_j_phrs_2024_107341 crossref_primary_10_1124_dmd_122_001011 crossref_primary_10_1016_j_drudis_2020_11_020 crossref_primary_10_1016_j_apsb_2023_06_015 crossref_primary_10_1021_acs_bioconjchem_9b00133 crossref_primary_10_1039_C5NP00091B crossref_primary_10_1021_acschembio_7b00302 crossref_primary_10_1021_mp500781a crossref_primary_10_1038_s41467_018_05217_1 crossref_primary_10_1021_acs_molpharmaceut_8b00275 crossref_primary_10_1016_j_drudis_2014_09_009 crossref_primary_10_1158_1535_7163_MCT_12_0405 crossref_primary_10_3762_bjoc_9_107 crossref_primary_10_1021_jo501839x crossref_primary_10_3390_cancers16193293 crossref_primary_10_1021_ja211098r crossref_primary_10_1038_s41467_021_27284_7 crossref_primary_10_1021_acschembio_6b00014 crossref_primary_10_1186_1476_4598_12_58 crossref_primary_10_1021_acs_jmedchem_7b00563 crossref_primary_10_1002_ange_201208373 crossref_primary_10_1021_jacsau_2c00448 crossref_primary_10_1021_jacs_9b02453 crossref_primary_10_1021_acs_joc_5b01373 crossref_primary_10_1039_c1cc15638a crossref_primary_10_1002_cmdc_201402169 crossref_primary_10_1016_j_bmc_2016_04_050 crossref_primary_10_1039_D4CB00203B crossref_primary_10_1016_j_pharmthera_2017_07_013 crossref_primary_10_1021_acs_orglett_5b00432 crossref_primary_10_1126_science_aar7785 crossref_primary_10_1021_jm4000209 crossref_primary_10_1016_j_bmcl_2018_03_040 crossref_primary_10_52547_ibj_25_3_140 crossref_primary_10_1016_j_bmc_2010_05_078 crossref_primary_10_1016_j_bmcl_2018_03_016 crossref_primary_10_1016_j_tetlet_2018_02_080 crossref_primary_10_1039_D1NP00065A crossref_primary_10_1021_jm201284m crossref_primary_10_1002_anie_201208373 crossref_primary_10_1360_TB_2021_1067 crossref_primary_10_1016_j_bmc_2021_116167 crossref_primary_10_3390_biomedicines9030290 crossref_primary_10_1021_acs_orglett_5b02957 crossref_primary_10_1038_nchembio_2448 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.2174/156802609789909812 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
EISSN | 1873-4294 |
ExternalDocumentID | 19903166 |
Genre | Research Support, Non-U.S. Gov't Journal Article Review |
GroupedDBID | CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-b465t-2613c08624d444ef7fe269cdc007c5330a42d52f1db31708896b0936523c3db2 |
IngestDate | Tue Jul 04 17:40:12 EDT 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-b465t-2613c08624d444ef7fe269cdc007c5330a42d52f1db31708896b0936523c3db2 |
PMID | 19903166 |
ParticipantIDs | pubmed_primary_19903166 |
PublicationCentury | 2000 |
PublicationDate | 2009-11-01 |
PublicationDateYYYYMMDD | 2009-11-01 |
PublicationDate_xml | – month: 11 year: 2009 text: 2009-11-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United Arab Emirates |
PublicationPlace_xml | – name: United Arab Emirates |
PublicationTitle | Current topics in medicinal chemistry |
PublicationTitleAlternate | Curr Top Med Chem |
PublicationYear | 2009 |
Score | 2.1513023 |
SecondaryResourceType | review_article |
Snippet | CC-1065, the duocarmycins and yatakemycin are members of a family of ultrapotent antitumour antibiotics that have been the subject of extensive investigations... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1494 |
SubjectTerms | Animals Antibiotics, Antineoplastic - chemistry Antibiotics, Antineoplastic - pharmacokinetics Antibiotics, Antineoplastic - therapeutic use Antineoplastic Agents, Alkylating - chemistry Antineoplastic Agents, Alkylating - pharmacology Antineoplastic Agents, Alkylating - therapeutic use Biological Products - chemistry Biological Products - pharmacology Biological Products - therapeutic use Drug Evaluation, Preclinical Humans Indoles - chemistry Indoles - pharmacology Indoles - therapeutic use Pyrrolidinones - chemistry Pyrrolidinones - pharmacology Pyrrolidinones - therapeutic use |
Title | Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products |
URI | https://www.ncbi.nlm.nih.gov/pubmed/19903166 |
Volume | 9 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT8IwFG5AX3wxGu-39ME3M2Vbu7FHQzREgyERE97IunaBBBiB8YB_xL_rOe0GFS9RXxbWMlj2fT2X7lwIuVTKCwR3U8cNoshhMo1hScHCiwXY_jAWcg-zkVtPQfOFPXR5t1J5s6KW5rm4Tl6_zCv5D6owBrhiluwfkF3-KAzAZ8AXjoAwHH-F8Ydsf1NOSZ8qHVi3CnJD47LYycDoiwZIxYAvYyflHPTZdLRIBuMrXecTk7NMIdiZbbuWpZzybIKlneHbxYt5LDFS9o1bxvP0s1m_EN9ykC-F_3NfDeU0NiFBWudZHY114uViPYWonZk2bo_DeG2XIirS9bSSMZK1HvoOKD9mi97IZpgtR8FvY18JeHSgcK-BB3UshgYuMGjTqG4isS3EJyMNuQuzvmvauvw8u1Z0u5yqkiq4H9hPtd0yKVd4Bzef_18XnzXXrDko2lDp7JDtwsOgt4Yuu6SixntElFShAAddUYXaVKFZSoEQ1FAFzwqq6ItwxqIKLahCS6rsk879XafRdIr2Go5gAc8d8J39BD1aJhljKg1TWLdRIhMwGxMMOo6ZJ7mXulKAkYnhcIGoRX7APT_xpfAOyMY4G6sjQsGmj3mY1jjuIqpaIlzpg2hXEUh4pkLvmByaJ9KbmBIqvfJZnXw7c0q2Vjw6I5sprFl1DgZgLi40HO9yGFpd |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chemical+and+biological+explorations+of+the+family+of+CC-1065+and+the+duocarmycin+natural+products&rft.jtitle=Current+topics+in+medicinal+chemistry&rft.au=Ghosh%2C+Nandita&rft.au=Sheldrake%2C+Helen+M&rft.au=Searcey%2C+Mark&rft.au=Pors%2C+Klaus&rft.date=2009-11-01&rft.eissn=1873-4294&rft.volume=9&rft.issue=16&rft.spage=1494&rft_id=info:doi/10.2174%2F156802609789909812&rft_id=info%3Apmid%2F19903166&rft_id=info%3Apmid%2F19903166&rft.externalDocID=19903166 |